<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">pmj</journal-id><journal-title-group><journal-title xml:lang="ru">Тихоокеанский медицинский журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Pacific Medical Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1609-1175</issn><publisher><publisher-name>TGMU</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">pmj-728</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL RESEARCHES</subject></subj-group></article-categories><title-group><article-title>ВЛИЯНИЕ СПЕЦИФИЧЕСКОЙ ИММУНОТЕРАПИИ РАКА ШЕЙКИ МАТКИ НА СОСТОЯНИЕ КЛЕТОЧНОГО ИММУНИТЕТА</article-title><trans-title-group xml:lang="en"><trans-title>EFFECT OF SPECIFIC IMMUNOTHERAPY OF CARCINOMA OF UTERINE CERVIX ON THE STATE OF CELLULAR IMMUNITY</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кенбаева</surname><given-names>Д. К.</given-names></name><name name-style="western" xml:lang="en"><surname>Kenbaeva</surname><given-names>D. K.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Манамбаева</surname><given-names>З. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Manambaeva</surname><given-names>Z. A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лазарев</surname><given-names>А. Ф.</given-names></name><name name-style="western" xml:lang="en"><surname>Lazarev</surname><given-names>A. F.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Городской онкологический диспансер</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Astana Municipal Oncological Center</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Государственный медицинский университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Semey State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Алтайский краевой онкологический диспансер</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Altai Regional Oncological Center</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>28</day><month>03</month><year>2014</year></pub-date><volume>0</volume><issue>1</issue><fpage>85</fpage><lpage>88</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Кенбаева Д.К., Манамбаева З.А., Лазарев А.Ф., 2014</copyright-statement><copyright-year>2014</copyright-year><copyright-holder xml:lang="ru">Кенбаева Д.К., Манамбаева З.А., Лазарев А.Ф.</copyright-holder><copyright-holder xml:lang="en">Kenbaeva D.K., Manambaeva Z.A., Lazarev A.F.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.tmj-vgmu.ru/jour/article/view/728">https://www.tmj-vgmu.ru/jour/article/view/728</self-uri><abstract><p>Оценивалась эффективность специфической иммунотерапии рака шейки матки в сочетании с лучевой терапией. Обследована 81 пациентка с раком шейки матки IIB и III стадии. Проводилась сочетанная лучевая терапия и комбинированное лечение: лучевая терапия и специфическая иммунотерапия (реинфузии аутолимфоцитов после инкубации с гомогенатом опухолевой ткани in vitro с добавлением интерлейкина-2). Определялись показатели клеточного иммунитета. Значимое увеличение показателей при комбинированной терапии зарегистрировано только для абсолютного содержания натуральных киллеров при IIB стадии и для относительного содержания Т-киллеров при III стадии рака. Нормализации содержания лимфоцитов всех изученных фенотипов в крови больных раком шейки матки достигнуто не было, что может служить основанием для разработки дополнительных способов активации клеточных механизмов in vivo.</p></abstract><trans-abstract xml:lang="en"><p>The object of research is to evaluate the efficacy of the specific immunotherapy of carcinoma of uterine cervix in a combination with the radiation therapy. Methods. The research covers 81 patients having cervical cancer from IIB to III grades. Conducted combined radiotherapy (41 cases) and combined treatment (40 cases): radiation therapy and specific immunotherapy, i.e. the reinfusions of lymphocytes after incubation with homogenates of the tumor tissue in vitro and addition of interleukin-2. Detected indicators of cellular immunity. Results. Significant increment of indicators due to the combined therapy registered exclusively for the absolute content of natural killer cells in IIB grade and for the relative content of killer T cells in III grade of the cancer. Normalization of the level of lymphocyte of all examined phenotypes in blood of the patients having carcinoma of uterine cervix failed to be achieved. Conclusions. Based on the results, the conclusion is that the efficacy of the used methods of stimulation of the antitumour immunity was insufficient and it suggests developing additional ways to activate the cellular mechanisms in vivo.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>злокачественные новообразования</kwd><kwd>лечение</kwd><kwd>лимфоциты</kwd></kwd-group><kwd-group xml:lang="en"><kwd>cancer</kwd><kwd>treatment</kwd><kwd>lymphocytes</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Гланц С. Медико-биологическая статистика / пер. с англ. М.: Практика, 1998. 459 с.</mixed-citation><mixed-citation xml:lang="en">Гланц С. Медико-биологическая статистика / пер. с англ. М.: Практика, 1998. 459 с.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Aguilar L.K., Guzik B.W., Aguilar-Cordova E. Cytotoxic immunotherapy strategies for cancer: mechanisms and clinical development // J. Cell. Biochem. 2011. Vol. 112, No. 8. P. 1969-1977.</mixed-citation><mixed-citation xml:lang="en">Aguilar L.K., Guzik B.W., Aguilar-Cordova E. Cytotoxic immunotherapy strategies for cancer: mechanisms and clinical development // J. Cell. Biochem. 2011. Vol. 112, No. 8. P. 1969-1977.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Berzofsky J.A., Terabe M., Wood L.V. Strategies to use immune modulators in therapeutic vaccines against cancer // Semin. Oncol. 2012. Vol. 39, No. 3. P. 348-357.</mixed-citation><mixed-citation xml:lang="en">Berzofsky J.A., Terabe M., Wood L.V. Strategies to use immune modulators in therapeutic vaccines against cancer // Semin. Oncol. 2012. Vol. 39, No. 3. P. 348-357.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Inamoto T., Azuma H. Immunotherapy of genitourinary malignancies // J. Oncol. 2012. Article ID 397267.</mixed-citation><mixed-citation xml:lang="en">Inamoto T., Azuma H. Immunotherapy of genitourinary malignancies // J. Oncol. 2012. Article ID 397267.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Gajewski T.F. Cancer immunotherapy // Mol. Oncol. 2012. Vol. 6, No. 2. P. 242-250.</mixed-citation><mixed-citation xml:lang="en">Gajewski T.F. Cancer immunotherapy // Mol. Oncol. 2012. Vol. 6, No. 2. P. 242-250.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Jordanova E.S., Gorter A., Ayachi O. [et al.]. Human leukocyte antigen class I, MHC class I chain-related molecule A, and CD8+/ regulatory T-cell ratio: which variable determines survival of cervical cancer patients? // Clin. Cancer Res. 2008. Vol. 14, No. 7. P. 2028-2035.</mixed-citation><mixed-citation xml:lang="en">Jordanova E.S., Gorter A., Ayachi O. [et al.]. Human leukocyte antigen class I, MHC class I chain-related molecule A, and CD8+/ regulatory T-cell ratio: which variable determines survival of cervical cancer patients? // Clin. Cancer Res. 2008. Vol. 14, No. 7. P. 2028-2035.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Krieger N., Bassett M.T., Gomez S.L. Breast and cervical cancer in 187 countries between 1980 and 2010 // Lancet. 2012. Vol. 379, No. 9824. P. 1391-1392.</mixed-citation><mixed-citation xml:lang="en">Krieger N., Bassett M.T., Gomez S.L. Breast and cervical cancer in 187 countries between 1980 and 2010 // Lancet. 2012. Vol. 379, No. 9824. P. 1391-1392.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Pandolfi F., Cianci R., Pagliari D. [et al.]. The immune response to tumors as a tool toward immunotherapy // Clin. Dev. Immunol. 2011. Article ID 894704.</mixed-citation><mixed-citation xml:lang="en">Pandolfi F., Cianci R., Pagliari D. [et al.]. The immune response to tumors as a tool toward immunotherapy // Clin. Dev. Immunol. 2011. Article ID 894704.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Reinis M., Stepanek I., Simova J. [et al.]. Induction of protective immunity against MHC class I-deficient, HPV16-associated tumours with peptide and dendritic cell-based vaccines // Int. J. Oncol. 2010. Vol. 36, No. 3. P. 545-551.</mixed-citation><mixed-citation xml:lang="en">Reinis M., Stepanek I., Simova J. [et al.]. Induction of protective immunity against MHC class I-deficient, HPV16-associated tumours with peptide and dendritic cell-based vaccines // Int. J. Oncol. 2010. Vol. 36, No. 3. P. 545-551.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Van den Broek M., von Boehmer L., Knuth A. Developments in cancer immunotherapy // Dig. Dis. 2010. Vol. 28, No. 1. P. 51-56.</mixed-citation><mixed-citation xml:lang="en">Van den Broek M., von Boehmer L., Knuth A. Developments in cancer immunotherapy // Dig. Dis. 2010. Vol. 28, No. 1. P. 51-56.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
